Market Newsdesk

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”).

Final voting results for the special meeting will be disclosed on Form 8-K filed by Paratek with the U.S. Securities and Exchange Commission.

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.

The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax.
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Paratek Pharmaceuticals, Inc. (the “Company”) and members of its senior management team and can typically be identified by words such as “believe,” “expect,” “estimate,” “predict,” “target,” “potential,” “likely,” “continue,” “ongoing,” “could,” “should,” “intend,” “may,” “might,” “plan,” “seek,” “anticipate,” “project” and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed transaction, similar transactions, prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company’s business; the commercial success of the Company’s products; the expected timing of the completion of the proposed transaction; the ability to complete the proposed transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the merger the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement and Plan of Merger, dated as of June 6, 2023, among the Company, Resistance Merger Sub, Inc. (“Merger Sub”) and Resistance Acquisition, Inc. (the “Merger Agreement”), including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the satisfaction of the conditions precedent to the consummation of the proposed transaction; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities; transaction costs; the risk that the merger will divert management’s attention from the Company’s ongoing business operations or otherwise disrupt the Company’s ongoing business operations; changes in the Company’s businesses during the period between now and the closing; certain restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the proposed transaction; the Company’s ability to continue as a going concern; the Company’s ability to maintain or expand regulatory approvals or commercialize the Company’s products; the results of any ongoing or future clinical trials may not satisfy U.S. or non-U.S. regulatory authorities; the regulatory approval process is expensive, time consuming and uncertain; the Company’s dependence on the commercial success of NUZYRA and, to a lesser extent, SEYSARA; the Company’s dependence on funding from BARDA; the Company’s substantial indebtedness; risk associated with litigation; the uncertainty associated with the current worldwide economic conditions and the continuing impact on economic and financial conditions in the United States and around the world, including as a result of COVID-19, rising inflation, increasing interest rates, natural disasters, military conflicts, including the conflict between Russia and Ukraine, terrorist attacks and other similar matters, and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to the Company and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. The information set forth herein speaks only as of the date hereof.

Stockholders

Morrow Sodali LLC
Email: [email protected]  
Phone: (800) 662-5200 or (203) 658-9400

Investor Relations

PJ Kelleher
LifeSci Advisors
Email: [email protected]
Phone: (617) 430-7579

Media Contacts

Paratek

Michael Lampe
Scient Public Relations
Email: [email protected]
Phone: (215) 995-0180

GREENWOOD VILLAGE, Colo., Sept. 18, 2023 (GLOBE NEWSWIRE) — Advanced Emissions Solutions, Inc. (NASDAQ: ADES) (the “Company” or “ADES”), a producer of activated carbon, and other environmentally efficient carbon products for use in purification, sustainable energy, sustainable materials and energy transition, today announced that Jeremy “Deke” Williamson has been appointed as Chief Operating Officer (“COO”) effective September 18, 2023.

Robert Rasmus, CEO of ADES commented, “I would like to welcome Deke to the ADES team in his role as COO. Deke is a proven leader. He has extensive experience optimizing plant operations and successfully completing construction and expansion projects on, or ahead of time. I know Deke shares our goal of ADES being the safest, lowest operating cost and most profitable company in the industry.”

Williamson added, “I am thrilled to become a part of the ADES team and believe we have a tremendous opportunity to help the world reduce carbon and chemical emissions through our growing platform of activated carbon solutions. ADES will be the only vertically integrated Granular Activated Carbon producer in North America, and I look forward to leveraging my prior operations experience to support the construction and completion of the expansion of ADES’s Red River and Corbin plants. We have a great mission focused on the need for innovative purification solutions and I’m excited to get to work.”

Mr. Williamson is the former Senior Vice President of Production and Distribution Operations at Hi-Crush, Inc., a fully integrated provider of proppant and logistics services for hydraulic fracturing operations. While at Hi-Crush, Williamson’s responsibilities largely revolved around managing multiple mining operations, strategic planning, and assisting the research and development teams. Prior to joining Hi-Crush in 2011, Williamson was the Plant Manager at Southeast Missouri Stone, a leader in infrastructure construction and maintenance. Williamson holds a BS in Business Management and MBA from the University of Phoenix.

About Advanced Emissions Solutions, Inc.

Advanced Emissions Solutions, Inc. serves as the holding entity for a family of companies that provide emissions solutions to customers in the power generation and other industries.

ADA brings together ADA Carbon Solutions, LLC, a leading provider of powder activated carbon (“PAC”) and ADA-ES, Inc., the providers of ADA® M-Prove™ Technology. We provide products and services to control mercury and other contaminants at coal-fired power generators and other industrial companies. Our broad suite of complementary products control contaminants and help our customers meet their compliance objectives consistently and reliably.

CarbPure Technologies LLC, (“CarbPure”), formed in 2015 provides high-quality PAC and granular activated carbon ideally suited for treatment of potable water and wastewater. Our affiliate company, ADA Carbon Solutions, LLC manufactures the products for CarbPure.

FluxSorb, LLC, formed in 2022, is an emerging technology company that introduces highly engineered activated carbons with a focus on the emerging remediation markets. Our vision is to partner with our customers to collaborate, develop and deploy best in class activated carbon solutions to meet even the most extreme challenges.

Arq is an environmental technology business founded in 2015 that has developed a novel process for producing specialty carbon products from coal mining waste. Arq has the technology and large-scale manufacturing facilities to produce a micro-fine hydrocarbon powder, Arq powder™, that can be used as a feedstock to produce activated carbon and as an additive for other products.

Caution on Forward-Looking Statements

Statements in this press release regarding the Company that are not historical facts, including statements concerning the Company’s ability to be the only vertically integrated Granular Activated Carbon Producer, are forward-looking statements within the meaning of applicable securities laws and regulations that involve risks and uncertainties and are not guarantees of future performance. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and other subsequent filings with the Securities and Exchange Commission. You should not place undue reliance on the forward-looking statements, which speak only as of the date made. The Company undertakes no duty to update any forward-looking statement that it may make, whether as a result of new information, future events or otherwise, except as may be required by applicable law, regulation or other competent legal authority.

Source: Advanced Emissions Solutions, Inc.

Investor Contact:

Alpha IR Group
Ryan Coleman or Chris Hodges
312-445-2870
[email protected]

AUSTIN, Texas, Sept. 18, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN), (“Volcon” or the “Company”), the first all-electric, off-road powersports company, announced on September 14, 2023 that it has agreed with its convertible noteholders to modify the terms of its convertible notes and implemented cost reduction strategies to provide the Company greater flexibility as it pushes toward the introduction of the first of its UTV models, the Stag, which the Company expects to begin delivering in October 2023.

The Company entered into a note amendment with its convertible noteholders pursuant to which the lenders agreed to, among other changes, extend the maturity of the outstanding convertible notes from February 24, 2024 to January 31, 2025 and modify certain covenants to allow the Company to execute its business strategy as it works toward the launch of the Stag. The amendment is subject to completion of a security agreement establishing a security interest in the assets of the Company for the benefit of the noteholders. “We appreciate the support of our noteholders in making these amendments in order to give us the flexibility to raise capital to support the launch of the Stag and the growth of our business,” said Jordan Davis, CEO. Davis continued, “With our Stag launch closing in, our ability to obtain funding to support manufacturing and to market the Stag to the public to generate consumer demand are key factors to our success.”

The Company recently implemented further cost reduction initiatives and is continuing to evaluate its cost structure to identify incremental savings. Davis notes, “We continue to build upon our previously announced cost reduction measures, such as closing manufacturing operations in favor of outsourced production and reducing headcount in various areas of the Company to support our vehicle development strategy.”

In addition, the Company has reduced cash expenses by agreeing to eliminate cash bonuses payable to the Company’s officers in favor of stock awards and the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer have voluntarily agreed to reduce their salaries by 10%. The Company’s board of directors has also agreed that all future quarterly board cash fees will be payable in the form of stock awards as well. Davis notes, “The Management Team and the Board know how important the Stag is to our Company, and we recognize we need to personally support the cash reduction initiatives to ensure our success.”

On September 13, 2023, the Company announced additional trim packages and pricing for the Stag. The initial response by existing reservation holders who made deposits and viewed new trim level selections has been positive. The Company continues to follow up with all pre-order reservation holders to make sure they are aware of the trim package options and answer any questions they may have. The Company also realized new customer preorders which further supports the Stag product line and the future of EV in powersports. The Company has two consumer lending firms providing financing to consumers, Synchrony Bank and Octane Roadrunner Financial, which can be found on Volcon.com or by contacting Volcon dealers for more information.

In addition, the Company’s sales team is connecting with dealers and distributors to place pre-orders. The overwhelming majority of dealers are committed to selling Volcon products and are excited that the Stag is finally coming to market. The Company is also working with a finance company to obtain a facility that will allow the Company to place Stags with dealers for small cash outlays allowing the Company to generate cash to reinvest in additional dealer placements. This facility will allow dealers to finance their Stag purchases.

About Volcon

Based in the Austin, Texas area, Volcon was founded as the first all-electric powersports company producing high-quality and sustainable electric vehicles for the outdoor community. Volcon electric vehicles are the future of off-roading, not only because of their environmental benefits, but also because of their near silent operation, which allows for a more immersive outdoor experience.

Volcon’s 2023 vehicle roadmap includes both motorcycles and UTVs hitting the market in North America. Its first product, the innovative Grunt, has been shipping to customers since late 2021 and combines a fat-tired physique with high-torque electric power and a near-silent drive train. Volcon just announced the launch of the Grunt EVO, an evolution of the original Grunt with a belt drive, an improved suspension and seat. Volcon also just announced the launch of the Runt LT, which is a fun-sized version of the groundbreaking Grunt, is better suited for small statured riders, more compact properties and trails, or as a pit bike at race events, while still delivering robust off-road capabilities. The Brat is Volcon’s first foray into the wildly popular eBike market for both on road and off-road riding and is currently being delivered to dealers across North America. Volcon is also launched and is currently delivering the Volcon Youth Line of dirt bikes for younger riders between the ages of 4 to 11. Volcon recently launched the Stag and entered the rapidly expanding UTV market. The Stag empowers the driver to explore the outdoors in a new and unique way that gas-powered UTVs cannot. The Stag offers the same thrilling performance of a standard UTV without the noise (or pollution), allowing the driver to explore the outdoors with all their senses.

Volcon Contacts

For Media: [email protected]

For Dealers: [email protected]

For Investors: [email protected]

For Marketing: [email protected]

For more information on Volcon or to learn more about its complete motorcycle and side-by-side line-up, visit: www.volcon.com

Forward-Looking Statements

Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements about the ability to agree upon a mutually acceptable security agreement with the note holders, the anticipated completion and timing of the delivery of the Stag vehicle and certain anticipated cost reductions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q filed with the SEC, which are available on the SEC’s website, www.sec.gov.

SOURCE: Volcon ePowersports, Inc.

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.

The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no standardized scoring method currently exists. Similar to standards established for PD-L1 immune checkpoint, there is a need to quantify VISTA expression in the tumor microenvironment (TME) to properly guide patient selection.

“We are excited to work with the Fred Hutchinson Cancer Center and tap into their cancer pathology expertise as we advance the clinical development of KVA12123,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta. “VISTA expression has the potential to be a clinically relevant biomarker that we can use to inform our Phase 2 clinical study design with KVA12123 and ultimately predict positive anti-tumor responses to treatment.”

VISTA is a negative immune checkpoint that suppresses T cell function in a variety of solid tumors. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Blocking VISTA induces an efficient polyfunctional immune response to address immunosuppression and drives anti-tumor responses.

KVA12123 is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope at both physiologic and acidic pH levels. KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. Initial clinical data from Kineta’s ongoing Phase 1/2 study of KVA12123 in advanced solid tumors is anticipated by end of 2023.

About Kineta

Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

Cautionary Statements Regarding Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” and other similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Kineta’s current beliefs, expectations and assumptions regarding the future of Kineta’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Such forward-looking statements are subject to a number of material risks and uncertainties including, but not limited to: the adequacy of Kineta’s capital to support its future operations (including its ability to complete the second tranche of the previously disclosed contemplated private placement in the fourth quarter of 2023) and its ability to successfully initiate and complete clinical trials; the difficulty in predicting the time and cost of development of Kineta’s product candidates; Kineta’s plans to research, develop and commercialize its current and future product candidates, including, but not limited to, KVA12123; the timing and anticipated results of Kineta’s planned pre-clinical studies and clinical trials and the risk that the results of Kineta’s pre-clinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials; the timing of the availability of data from Kineta’s clinical trials; the timing of any planned investigational new drug application or new drug application; the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact of government laws and regulations; the timing and outcome of Kineta’s planned interactions with regulatory authorities; Kineta’s ability to protect its intellectual property position; Kineta’s estimates regarding future revenue, expenses, capital requirements and need for additional financing; the intended use of proceeds from the registered direct offering completed in April 2023; and those risks set forth under the caption “Risk Factors” in the company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2023, and Quarterly Report on Form 10-Q filed with the SEC on August 11, 2023, as well as discussions of potential risks, uncertainties and other important factors in Kineta’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Except as required by law, Kineta undertakes no obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kineta, Inc. :

Jacques Bouchy
EVP Investor Relations & Business Development
+1 206-378-0400
[email protected]

Investor Relations:

John Mullaly
LifeSci Advisors, LLC
[email protected]

Source: Kineta, Inc.

MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) announces today that Rhodri J. Harries, Executive Vice-President, Chief Financial and Administrative Officer and Chuck Ward, President, Sales, Marketing, and Distribution will participate in a fireside chat and one-on-one meetings with investors at the 27^th Scotiabank Annual Back to School Conference in Toronto on September 20, 2023.

About Gildan

Gildan is a leading manufacturer of everyday basic apparel which markets its products in North America, Europe, Asia Pacific, and Latin America, under a diversified portfolio of Company-owned brands, including Gildan®, American Apparel®, Comfort Colors®, GOLDTOE®, Peds®, in addition to the Under Armour® brand through a sock licensing agreement providing exclusive distribution rights in the United States and Canada. The Company’s product offerings include activewear, underwear and socks, sold to a broad range of customers, including wholesale distributors, screenprinters or embellishers, as well as to retailers that sell to consumers through their physical stores and/or e-commerce platforms, and to global lifestyle brand companies.

Gildan owns and operates vertically integrated, large-scale manufacturing facilities which are primarily located in Central America, the Caribbean, the United States, and Bangladesh. Gildan operates with a strong commitment to industry-leading labour, environmental and governance practices throughout its supply chain in accordance with its comprehensive ESG program embedded in the Company’s long-term business strategy. More information about the Company and its ESG practices and initiatives can be found at www.gildancorp.com.

EV Charging Leader
Build
s
Upon
Synergies
, Production
and Cost
Efficiencies
as Electric Vehicle Market Continues to Expand Globally

Miami Beach, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) —
Blink Charging Co. (NASDAQ: BLNK) (“Blink”), a global leading manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, today announced the Blink Board of Directors has approved changes made to Blink’s executive leadership team with the appointment of Michael Battaglia, (formerly Chief Revenue Officer) as Chief Operations Officer; Jim Nemec, (formerly VP Sales and Business Development) as Chief Revenue Officer; and Siddhartha Kodgi, (formerly Sr. Director Operations) as Vice President of Operations. The Company also announced the departure of Mark Pastrone from his role as Chief Operations Officer.

Following its record Q2 earnings announcement of nearly $33 million, the strongest in Company history, Blink will continue to focus on enhancing and building upon its strong synergies following the acquisition of six companies over the last three years. Blink will remain committed to driving cost efficiencies, revenue generation, in-house production, customer service enhancements, and market share gains.

“These are exciting times for Blink and the industry, and these leadership moves will enable the Company to continue its steady growth as we tap into the expertise and skill sets of these seasoned professionals. We are saddened to see Mark leave the Company following his long career within our industry, and we thank him for his contributions and the positive impact he has had,” said Brendan Jones, President and Chief Executive Officer of Blink Charging. “We are proud to have Mike, Jim and Siddhartha lead our efforts delivering exceptional customer experiences and increased productivity for Blink.”

Mr. Jones continued, “Together, this formidable team helps solidify us as one company, provides bottom line savings and is dedicated to building a vertically integrated EV infrastructure, globally.”

Mr. Battaglia previously served as Blink’s Chief Revenue Officer (CRO) since December 2022 and will assume the position of Chief Operations Officer (COO), succeeding the outgoing Pastrone. Moving forward, Mr. Battaglia will oversee Blink’s sales, business development and all aspects of operations, playing a vital role in the Company’s expansion in the U.S. and globally. Prior to joining Blink, Mr. Battaglia served as Vice President of Sales at JD Power.

“I am honored to take on this new role during a time of significant growth for Blink. There is great opportunity for the Company, and I look forward to working with my colleagues around the world to help bring Blink to the next level of excellence in the EV charging market,” said Battaglia. “I remain hyper-focused and committed to optimizing Blink’s operations, and to produce quality charging equipment and providing a best-in-class customer experience.”

Mr. Nemec has served as Vice President of Sales and Business Development for Blink since 2022, increasing revenues and building strong relationships in both the private and public sectors. He previously served as Director of Channel & Government Sales for SemaConnect, which was acquired by Blink in 2022. In his new capacity, Mr. Nemec will oversee Blink’s global sales organization, develop go-to-market strategies, and identify global expansion opportunities.

“Blink has been a leader in the industry, and I’m excited to have this opportunity to lead and advance our mission and bring Blink to the next stage of growth. Having worked side-by-side with Mike and Siddhartha, I look forward to continuing our team’s success and developing new markets as we advance electrification around the world,” said Nemec.

Mr. Kodgi has served as Sr. Director of Operations since 2022, following Blink’s acquisition of SemaConnect, where he had served since 2015. Prior to the acquisition, Mr. Kodgi was responsible for managing field services, design services, production, and supply chain for SemaConnect.

“I look forward to applying my passion for technology, scaling operations and driving efficiencies in this new role and to working with my colleagues to continue to lead the industry in EV charging solutions,” commented Kodgi.

Mr. Pastrone has served as COO for Blink since December 2022, following its acquisition of SemaConnect and has played a key role in building synergies and operational efficiencies for customer service, installation operations, and charger production. Prior to his role at SemaConnect, Pastrone worked in the aerospace industry, and led the development of several commercial space ventures at Orbital Sciences Corporation including GeoEye, which was acquired by Maxar.

Battaglia, Nemec and Kodgi are part of an accomplished executive management team, comprised of an unparalleled group of industry experts at all levels of management throughout the Blink organization. The industry as a whole will benefit from the amassed talent that includes Blink’s President and CEO, Brendan Jones and a former EV executive at Nissan, Electrify America and Evgo, along with Ritsaart Van Montfrans, Blink Director and the former owner and CEO of New Motion; and Harjinder Bhade, Blink CTO and a founder of ChargePoint. This dynamic team of EV industry leaders, along with the highly experienced Blink senior management, position Blink as a formidable provider of EV solutions and establishes Blink as a leader in the industry.

###

About Blink Charging

Blink Charging Co. (Nasdaq: BLNK), a global leader in electric vehicle (EV) charging equipment, has contracted, sold, or deployed nearly 78,000 charging ports worldwide, many of which are networked EV charging stations, enabling EV drivers to easily charge at any of Blink’s charging locations. Blink’s principal line of products and services includes the Blink EV charging network (“Blink Network”), EV charging equipment, EV charging services, and the products and services of recent acquisitions, including SemaConnect, Blue Corner, BlueLA and Envoy. The Blink Network uses proprietary, cloud-based software that operates, maintains, and tracks the EV charging stations connected to the network and the associated charging data. With global EV purchases forecasted to half of passenger cars sold in the US by 2030, Blink has established key strategic partnerships for rolling out adoption across numerous location types, including parking facilities, multifamily residences and condos, workplace locations, health care/medical facilities, schools and universities, airports, auto dealers, hotels, mixed-use municipal locations, parks and recreation areas, religious institutions, restaurants, retailers, stadiums, supermarkets, and transportation hubs.

For more information, please visit https://www.blinkcharging.com/.

Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Blink Charging and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described in Blink Charging’s periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Blink Charging undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Blink Media Contact

Jon Myers
[email protected]
305-521-0200 ext. 266

Blink Investor Relations Contact

Vitalie Stelea
[email protected]
305-521-0200 ext. 446